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Review of Mellone et al.
The microtubule-binding protein tau is
widely expressed in neurons, where it sup-
ports the assembly and stabilization ofmi-
crotubules (Fong et al., 2013; Spillantini
and Goedert, 2013). Under normal phys-
iological conditions, tau lacks secondary
structure and is highly soluble. However,
posttranslational modifications, includ-
ing hyperphosphorylation and trunca-
tions, are associated with the formation of
pathological, insoluble tau-containing ag-
gregates (Zhao et al., 2010). These intra-
cellular aggregates are amajor hallmark of
various neurodegenerative diseases. These
diseases, collectively known as tauopa-
thies, include frontotemporal dementia
(FTDP-17), corticobasal degeneration,
progressive supranuclear palsy, and Alz-
heimer’s disease (Spillantini and Goedert,
2013). While these diseases differ in their
clinical manifestations and the neuronal
populations affected, all are characterized
by hyperphosphorylated tau, a state that
renders the protein unable to stabilize mi-
crotubules and support axonal transport
(Giacobini andGold, 2013). Although tau
aggregates are associatedwith neurotoxic-
ity and are considered to be deleterious,
the mechanisms underlying these detri-
mental effects are still under investigation.
Several models that mimic specific as-
pects of tauopathy have been developed.
Although in vivo transgenic models of
tauopathies have provided insight into the
pathology, candidate drugs that are useful
in thesemodels often fail as potential ther-
apeutics in patients (Fong et al., 2013),
making the extent of their clinical value
unclear. Several in vitro models in which
key hallmarks of tau pathology were re-
produced have also been developed (Mel-
lone et al., 2013), making it possible to
study specific aspects of tau pathology in
an isolated setting. These models may
provide useful knowledge about tau pa-
thology while limiting interference of
other factors. In one in vitro model, ex-
pression of mutated, aggregation-prone
(K280) tau repeat domains was induced
with doxycyclin in neuroblastoma lines
(Khlistunova et al., 2007). In a different
model, primary neuronal cell cultures
were exposed to the 306VQIVYK311 hexa-
meric peptide, a fragment of the third
repeat domain of tau. This hexameric
peptide was made cell-permeable by a
special arginine tag and consequently self-
assembled into fibrils after cell invasion
(Zhao et al., 2010).
These in vitro models allow the study
of the formation of tau-containing fibrils
and aggregates and may be amenable for
high-throughput screening of potential
therapeutics (Zhao et al., 2010). Their ad-
vantages, however, are accompanied by
several disadvantages. Although neuro-
blastoma lines have the advantage of un-
limited proliferation and are therefore
suitable for screening large numbers of
compounds, theymay respond differently
to genetic modifications or treatments
than normal neurons do. This creates a
major hurdle for clinical application
(Shastry et al., 2001). The application of
the hexameric peptide may provide new
insights into tau fibrillization. However,
the use of the specific hexameric peptides
has limitations in the light of drug screen-
ing, because only these added peptides ag-
gregate, not endogenous tau. A cellular
model that develops tau pathology with-
out external manipulations would be
preferable, because it may better mimic
pathological processes found in patients.
A disadvantage of all current models is
that they shownoor only inconsistent lev-
els of spontaneous tau pathology. There-
fore, new, high-quality in vitro models
that mimic human tau dysfunction are
needed to gain insights into the processes
underlying these diseases and to develop
effective treatments.
Mellone et al. (2013) recently created a
model of tauopathy using dorsal root gan-
glion neurons (DRGs) frommice carrying
the human P301S mutation of the tau-
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encodingMAPT gene under aThy1.2 pro-
moter. In humans, the P301S mutation
causes FTDP-17, producing an early onset
of symptoms (Allen et al., 2002). Half of
the DRGs taken from 3-month-old mice
containing human tau had spontaneous
tau hyperphosphorylation after 8weeks in
culture. The tau pathology observed in
cultured DRGs retained the characteris-
tics and mimicked the symptoms that are
found in the brains of both transgenic
mice and patients. The pathology was
demonstrated using antibodies AT8,
AT100, and PHF-1, which are directed
against different hyperphosphorylated
epitopes of tau, and with the HT7 anti-
body, which recognizes human tau. DRGs
cultured from 1-, 3-, and 5-month-old
mice showed increased levels of AT8 and
AT100 staining, which further increased
without other external manipulations by
8 weeks in culture. In addition, HT7
DRGs had abnormal axons and decreased
mitochondrial transport similar to those
seen in human tau pathology. AT8
HT7 DRGs had a shorter survival time
than AT8HT7 DRGs. Moreover, AT8
labeling appeared to be the earliest sign of
tau pathology in this in vitro model, sug-
gesting that AT8 labeling can be used as a
fast read-out for tau hyperphosphoryla-
tion. Finally, paired helical filaments were
detected by MC-1 staining in the DRG-
model (Mellone et al., 2013). Therefore,
the DRG model may provide a means by
which hyperphosphorylation and fibrilli-
zation of tau can be studied to elucidate
the pathological process of tau pathology
and to screen effects of novel drugs.
Despite the usefulness of the mouse
DRG model developed by Mellone et al.
(2013), appropriate human-derived cell
culture models might resemble human
tau pathology more closely. Fong et al.
(2013) recently illustrated the applicabil-
ity of induced pluripotent stem (iPS) cells
in disease modeling and drug screening
for tauopathies. In this model, iPS cells
derived from an individual carrying an
A152T mutation of the MAPT gene were
used to generate neurons. With specific
zinc finger nucleases, Fong et al. (2013)
induced site-specific double-stranded
DNA breaks, replacing the mutant allele
with a wild-type nucleotide sequence. Us-
ing this technique, isogenic lines were cre-
ated that contained one of three different
gene doses: zero, one, or two copies of the
A152T mutation. The A152A/T cells con-
taining one copy showed increased
amounts of axonal degeneration, AT8
staining, and caspase-3-dependent tau
fragmentation. These effects were in-
creased even further in the A152T/T cell
line, containing two copies of themutated
gene.
Like previously developed cellular
models of tauopathies, those developed by
Mellone et al. (2013) and Fong et al.
(2013) have both advantages and disad-
vantages. The clear advantage of iPS cells
is the possibility of using human cells as a
model. The use of iPS cells may be supe-
rior to the DRG model because it
provides the opportunity to develop
patient-specific treatments by taking pa-
tients’ genetic background into account.
However, although the genetics of the
iPS-derived neurons may be identical to
the cells being modeled, the epigenome of
these cells may still differ. Moreover, the
model of Fong et al. (2013) requires zinc
finger nucleases to ensure genetic control-
lability and to generate control groups.
The DRG-model of Mellone et al. (2013)
does not require additional techniques to
create control groups. Therefore, this
model might be more useful for large
scale, high-throughput screening in early
stages of drug development. After all,
identifying novel, effective drugs for
tauopathies is of major importance given
that no effective treatments are yet avail-
able (Giacobini and Gold, 2013).
A drawback of the DRG model is that
these sensory neurons are not usually im-
plicated in tauopathies. Moreover, only
50% of the cultured HT7DRGs had hy-
perphosphorylation, as shown by the AT8
staining (Mellone et al., 2013). However,
the increasing number of HT7AT8
DRGs implies that the pathology pro-
gresses over time and ultimately more of
the DRGs may be affected. Hence, the
progression of tau hyperphosporylation
in DRGs may resemble human pathology
in this aspect. Moreover, DRGs are well
suited for studying axonal outgrowth,
guidance, and stability. Therefore, they
might be helpful in studying cytoskeletal
integrity, which is highly associated with
tau-dysfunction (Stoppelkamp et al., 2011).
In addition, the ability to culture the DRGs
for a relatively long period compared with,
for example, cortical neurons, enables as-
sessment of the effects of pharmaceutical
compounds on the formation of paired he-
lical filaments and aggregates over a times-
pan of several weeks. Targeted disruption of
specific steps in the formation of aggregates
and filaments in such longitudinal studies
may provide insight in the question of
which stage of the aggregation formation of
tau fibrils is most neurotoxic.
As noted above, the DRG model will
likely prove useful. Nonetheless, altera-
tions based on previous research might
further improve its value in drug screening.
There are indications that endogenous
murine tau interferes with transgenic, hu-
man tau during the development of tau
pathology. Studies report either acceler-
ated human tau aggregationwhenmurine
tau is absent (Ando et al., 2011) or an in-
crease of human hyperphosphorylated
tau and neurofibrillary tangle formation
in the presence of murine tau (Baglietto-
Vargas et al., 2014). Therefore, knocking
out murine tau in the P301S-background
might further improve the representative
value of the DRG model. Moreover, as il-
lustrated by Fong et al. (2013) regulation
of tau assembly and hyperphosphoryla-
tion are gene-dose-dependent. Extending
the transgenic lines with a variety of
P301S-htau insertions may therefore pro-
vide a way of studying this concentration
effect at the level of DRGs. Furthermore,
since tau truncations are observed in
tauopathies (Zhao et al., 2010), it would
be interesting to test whether tau is also
fragmented in the DRG model.
In conclusion, Mellone et al. (2013)
have created a novel cell model for tau
pathology in which tau hyperphosphory-
lation and aggregation develop without
external manipulation. DRG neurons may
not be as long-lived as neuroblastoma cells,
but they appear to be more similar to the
neurons that should eventually be targeted
in the clinic. The use of patient-derived iPS
cells provides an unprecedented tool for
studying human tau pathology, but it cer-
tainly does not exclude the use of the DRG
model. Although DRGs are not usually af-
fected in tauopathies, Mellone et al. (2013)
clearly demonstrate that the model resem-
bles the development of pathology found in
human tauopathies. The ability to culture
the DRGs for 8 weeks makes this model
a useful tool in the testing and develop-
ment of drugs against tauopathies and
to study the underlying mechanisms of
tau pathology.
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